Klaviyo, Inc.
KVYO NYSE Services-Prepackaged Software Financials FY2021βFY2025
What Klaviyo, Inc. does
No business description yet.
- Legal name
- Klaviyo, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 10, 2026
- Accession Β· CIK
- 0001835830-26-000007
0001835830
Revenue and margins
Klaviyo, Inc. had $1.2B of revenue in fiscal 2025, up 31.6% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $209M in fiscal 2025, 16.9% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Klaviyo, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 9.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably Klaviyo, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $328M | $386M | $739M | $881M | $1.1B |
| Interest coverage | β9,904.1x | β | β | β | β |
| Current ratio | β | 5.0x | 6.2x | 4.9x | 4.3x |
| Quick ratio | β | 5.0x | 6.2x | 4.9x | 4.3x |
| Total assets | β | $629M | $1.1B | $1.3B | $1.6B |
| Total liabilities | β | $133M | $174M | $239M | $384M |
| Shareholders' equity | β$2.2B | β$1.0B | $915M | $1.0B | $1.2B |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | β / 5 | 4 / 8 | 5 / 8 | 4 / 8 |
| Accruals ratio | β | β4.1% | β49.8% | β18.0% | β17.5% |
| Altman Z'' | β | β17.02 | 5.13 | 5.95 | 5.01 |
5 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $291M | $473M | $698M | $937M | $1.2B |
| Gross profit | $206M | $345M | $520M | $716M | $921M |
| Research and development | $65.6M | $104M | $262M | $238M | $291M |
| Operating income | β$79.2M | β$55.0M | β$331M | β$84.1M | β$67.8M |
| Interest expense | $0.0M | $0.0M | $0.0M | β | β |
| Pretax income | β$79.1M | β$49.1M | β$307M | β$43.7M | β$30.5M |
| Income tax | $0.3M | $0.1M | $1.2M | $2.5M | $1.3M |
| Net income | β$79.4M | β$49.2M | β$308M | β$46.1M | β$31.8M |
| Diluted EPS | β$0.36 | β$0.21 | β$1.27 | β$0.17 | β$0.11 |
| Diluted shares | 0.22B | 0.23B | 0.24B | 0.27B | 0.29B |
| Cash flow | |||||
| Cash from operations | β$22.7M | β$23.6M | $119M | $166M | $218M |
| Capital expenditure | $13.0M | $15.8M | $3.7M | $5.9M | $9.5M |
| Free cash flow | β$35.8M | β$39.4M | $116M | $160M | $209M |
| Depreciation and amortization | $5.3M | $9.0M | $13.7M | $17.7M | $18.6M |
| Stock-based compensation | $35.2M | $6.8M | $341M | $135M | $162M |
| Share buybacks | $140M | $0.0M | $0.0M | β | β |
| Dividends and buybacks | $140M | $0.0M | $0.0M | β | β |
| Balance sheet | |||||
| Cash and short-term investments | $328M | $386M | $739M | $881M | $1.1B |
| Current assets | β | $428M | $803M | $980M | $1.2B |
| Current liabilities | β | $85.0M | $131M | $200M | $282M |
| Property and equipment, net | β | $45.8M | $43.5M | $48.2M | $80.3M |
| Total assets | β | $629M | $1.1B | $1.3B | $1.6B |
| Total liabilities | β | $133M | $174M | $239M | $384M |
| Preferred stock | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$2.2B | β$1.0B | $915M | $1.0B | $1.2B |
| Margins | |||||
| Gross margin | 70.9% | 72.9% | 74.5% | 76.4% | 74.7% |
| Operating margin | β27.3% | β11.6% | β47.4% | β9.0% | β5.5% |
| EBITDA margin | β25.4% | β9.7% | β45.4% | β7.1% | β4.0% |
| Net margin | β27.3% | β10.4% | β44.2% | β4.9% | β2.6% |
| FCF margin | β12.3% | β8.3% | 16.6% | 17.1% | 16.9% |
| Returns | |||||
| Return on capital employed | β | β10.1% | β34.5% | β7.8% | β5.2% |
| Return on equity | β | β | β | β4.7% | β2.8% |
| Return on assets | β | β7.8% | β35.9% | β3.9% | β2.2% |
| Return on tangible equity | β | β | β33.7% | β4.5% | β2.7% |
| Growth | |||||
| Revenue growth | β | 62.7% | 47.7% | 34.3% | 31.6% |
| FCF growth | β | β | β | 38.3% | 30.3% |
| Share count change | β | 4.1% | 5.7% | 9.7% | 9.2% |
| Financial health | |||||
| Interest coverage | β9,904.1x | β | β | β | β |
| Current ratio | β | 5.0x | 6.2x | 4.9x | 4.3x |
| Quick ratio | β | 5.0x | 6.2x | 4.9x | 4.3x |
| Capital allocation | |||||
| Capex / revenue | 4.5% | 3.3% | 0.5% | 0.6% | 0.8% |
| Stock comp / revenue | 12.1% | 1.4% | 48.8% | 14.4% | 13.1% |
| Payouts / FCF | β | β | 0.0% | β | β |
| Quality scores | |||||
| Piotroski F-score | β | β | 4.0 | 5.0 | 4.0 |
| Altman Z'' | β | β17.0 | 5.1 | 5.9 | 5.0 |
| Accruals ratio | β | β4.1% | β49.8% | β18.0% | β17.5% |
Source: SEC EDGAR XBRL filings (CIK 0001835830). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.